semaglutide cardiovascular outcomes study 2025 news Beyond obesity: Novo's SELECT re-defines risk management VisualAbstract: Semaglutide and Cardiovascular Outcomes

Animal studies show this can boost resveratrol blood levels by over 1500%

Compounded semaglutide may not have the same quality control measures, which could lead to variations in the drugs strength and purity

7 In patients who meet these criteria, the ADA preferably recommends use of a GLP-1 RA with proven cardiovascular benefit or an SGLT-2 inhibitor with proven cardiovascular benefit provided they have adequate kidney function

78 revealed that patients who underwent bariatric surgery had significantly lower femoral neck BMD compared to non-surgical controls, whereas lumbar spine BMD did not differ significantly between the groups

Among them, the study of Niu et al

People who stopped Semaglutide regained 50-63% of their prior weight loss within a year